Dr. John Shaughnessy, Director of Basic Research and Director of the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics
The Myeloma Institute is at the forefront of research. With a dedicated faculty conducting clinical as well as basic science research, we are at the cutting edge of scientific breakthroughs. Our patients benefit from the rapid transmission of laboratory findings to daily care in the clinical setting.
The Myeloma Institute for Research and Therapy was awarded a $17.9 million grant from the National Cancer Institute to study strategies for controlling the growth of multiple myeloma. Overall goals of the research are to
Develop increased understanding of the genetic basis and clinical
and biological behavior of myeloma
Improve diagnostic capabilities
Further study risk factors and prognostic indicators with goal
of individualizing each patient’s treatment
To view Myeloma Institute abstracts from the 49th annual meeting of the American Society of Hematology (December 2007 click on http://www.abstracts2view.com/hem07/ Register, according to instructions. After you have registered and are at the page entitled "Sessions Index" click on Authors tab and then search for Barlogie
Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD Jr, Sawyer JR, Kuehl WM.
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Genes Chromosomes Cancer, 2008 Jul;47(7);573-90. PMID: 18381641
Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB.
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma.
Clin Cancer Res, 2008 May 1;14(9);2775-84. PMID: 18451245
Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B.
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Br J Haematol, 2008 May;141(4);433-44. PMID: 18371114
Li X, Pennisi A, Yaccoby S.
Role of decorin in the antimyeloma effects of osteoblasts.
Blood, 2008 Apr 24; PMID: 18436739
Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B.
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Leukemia, 2008 Apr 24; PMID: 18432260
Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B, Crowley J.
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Cancer, 2008 Apr 23; PMID: 18433012
Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J.
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Cancer, 2008 Apr 15;112(8);1754-64. PMID: 18300230
Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr.
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Bone, 2008 Apr;42(4);669-80. PMID: 18294945
Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr, Anaissie E, Crowley J, Barlogie B.
Suppression of abnormal karyotype predicts superior survival in multiple myeloma.
Leukemia, 2008 Apr;22(4);850-5. PMID: 18200039
Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK.
Expression and mutation status of candidate kinases in multiple myeloma.
Leukemia, 2008 Apr;22(4);889-90. PMID: 18414494
Matsui S, Yamanaka T, Barlogie B, Shaughnessy JD Jr, Crowley J.
Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma.
Stat Med, 2008 Mar 30;27(7);1106-20. PMID: 17680552
Qiang YW, Shaughnessy JD Jr, Yaccoby S.
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.
Blood, 2008 Mar 14; PMID: 18344425
Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy JD Jr, Zhan F.
An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
Blood, 2008 Mar 13; PMID: 18337559
Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B.
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Br J Haematol, 2008 Mar;140(6);625-34. PMID: 18302711
Tian E, Landowski TH, Stephens OW, Yaccoby S, Barlogie B, Shaughnessy JD Jr.
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma.
Mol Cancer Ther, 2008 Mar;7(3);500-9. PMID: 18319333
Yaccoby S, Zhan F, Shaughnessy J.
Cell lines of hyperdiploid myeloma, are we there yet? - response to Chng & Fonseca.
Br J Haematol, 2008 Mar;140(5);580-581. PMID: 18275436
Matsui S, Zeng S, Yamanaka T, Shaughnessy J.
Sample size calculations based on ranking and selection in microarray experiments.
Biometrics, 2008 Mar;64(1);217-26. PMID: 17680829
Barlogie B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Crowley J.
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more.
Leukemia, 2008 Feb 28; PMID: 18305551
Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr.
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Blood, 2008 Feb 27; PMID: 18305214
van Rhee F, Crowley J, Barlogie B.
Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness.
Blood, 2008 Feb 15;111(4);2491. PMID: 18263792
Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Blood, 2008 Feb 1;111(3);1309-17. PMID: 17947507
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, .
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Leukemia, 2008 Feb;22(2);414-23. PMID: 18094721
Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr.
Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
Leukemia, 2008 Feb;22(2);406-13. PMID: 18046446
Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B.
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Blood, 2008 Jan 15;111(2);968-9. PMID: 18182586
Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M.
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Blood, 2008 Jan 15;111(2);806-15. PMID: 17934070
Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J.
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Blood, 2008 Jan 1;111(1);94-100. PMID: 17895401
Gokden N, Barlogie B, Liapis H.
Morphologic heterogeneity of renal light-chain deposition disease.
Ultrastruct Pathol, 2008 Jan-Feb;32(1);17-24. PMID: 18300034
Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B.
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Clin Cancer Res, 2007 Dec 1;13(23);7073-9. PMID: 18056185
Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J.
The Arkansas approach to therapy of patients with multiple myeloma.
Best Pract Res Clin Haematol, 2007 Dec;20(4);761-81. PMID: 18070718
Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F.
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
J Immunother, 2007 Nov-Dec;30(8);847-54. PMID: 18049337
Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G.
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
Blood Coagul Fibrinolysis, 2007 Oct;18(7);595-8. PMID: 17890944
Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD.
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Blood, 2007 Sep 15;110(6);2041-8. PMID: 17536013
Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q.
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
Blood, 2007 Sep 1;110(5);1587-94. PMID: 17515399
Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S.
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
Br J Haematol, 2007 Sep;138(6);802-11. PMID: 17760811
Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G.
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Am J Hematol, 2007 Sep;82(9);831-3. PMID: 17546639
Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E.
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer.
Cancer, 2007 Aug 15;110(4);830-4. PMID: 17607669
van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B.
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Blood, 2007 Aug 1;110(3);827-32. PMID: 17416735
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell, 2007 Aug;12(2);115-30. PMID: 17692804
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Br J Haematol, 2007 Jul;138(2);176-85. PMID: 17593024
van Rhee F, Crowley J, Barlogie B.
Allografting or autografting for myeloma.
N Engl J Med, 2007 Jun 21;356(25);2646-8; author reply 2646-8. PMID: 17582078
Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD Jr.
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
Blood, 2007 Jun 1;109(11);4995-5001. PMID: 17303695
Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B.
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Br J Haematol, 2007 Jun;137(6);530-6. PMID: 17489983
Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD Jr.
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Blood, 2007 May 15;109(10);4470-7. PMID: 17255354
Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD.
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
J Biol Chem, 2007 May 4;282(18);13326-33. PMID: 17347152
Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G.
Hyperammonemia and encephalopathy in patients with multiple myeloma.
Am J Hematol, 2007 May;82(5);414-5. PMID: 17133420
Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK.
Expression and mutation status of candidate kinases in multiple myeloma.
Leukemia, 2007 May;21(5);1124-7. PMID: 17344920
Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJ, Ritter G, Durie B, Crowley J, Shaughnessy JD Jr, Scanlan MJ, Gure AO, Barlogie B, Dhodapkar MV.
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
J Exp Med, 2007 Apr 16;204(4);831-40. PMID: 17389240
Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood, 2007 Apr 15;109(8);3177-88. PMID: 17185464
Gokden N, Zangari M, Elici F, Barlogie B, Kumar J.
Potential effect of zoledronate therapy in heavy proteinuria.
Clin Nephrol, 2007 Apr;67(4);263-5. PMID: 17474565
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ.
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
J Clin Oncol, 2007 Mar 20;25(9);1121-8. PMID: 17296972
Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B.
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Blood, 2007 Mar 15;109(6);2276-84. PMID: 17105813
Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr.
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
Blood, 2007 Mar 1;109(5);2106-11. PMID: 17068150
Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr.
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Otolaryngol Head Neck Surg, 2007 Mar;136(3);396-400. PMID: 17321866
Gokden N, Cetin N, Colakoglu N, Kumar J, Abul-Ezz S, Barlogie B, Liapis H, Walker PD.
Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy.
Ultrastruct Pathol, 2007 Mar-Apr;31(2);141-9. PMID: 17613994
Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr.
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Blood, 2007 Feb 15;109(4);1692-700. PMID: 17023574
Dib A, Barlogie B, Shaughnessy JD Jr, Kuehl WM.
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.
Blood, 2007 Feb 1;109(3);1337-8. PMID: 17244692
Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, Walker R, Hollmig K, Shaughnessy JD Jr, Epstein J, Krishna S, Crowley J, Barlogie B.
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Br J Haematol, 2007 Feb;136(3);393-9. PMID: 17156398
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA.
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
Mol Endocrinol, 2007 Feb;21(2);486-98. PMID: 17068196
Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF.
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
BMC Genomics, 2007;8302. PMID: 17764563
Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q.
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
Cancer Cell, 2006 Oct;10(4);295-307. PMID: 17045207
Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Bone Marrow Transplant, 2006 Oct;38(7);501-6. PMID: 16980998
Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J.
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Br J Haematol, 2006 Oct;135(2);158-64. PMID: 16939489
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr.
The molecular classification of multiple myeloma.
Blood, 2006 Sep 15;108(6);2020-8. PMID: 16728703
Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr.
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Blood, 2006 Sep 1;108(5);1724-32. PMID: 16705089
Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G.
Response to bortezomib and activation of osteoblasts in multiple myeloma.
Clin Lymphoma Myeloma, 2006 Sep;7(2);109-14. PMID: 17026821
Lazarevic V, Wahlin A, Hultdin M, Zhan F, Shaughnessy J.
Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.
Leuk Lymphoma, 2006 Sep;47(9);1987-8. PMID: 17065022
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, .
International uniform response criteria for multiple myeloma.
Leukemia, 2006 Sep;20(9);1467-73. PMID: 16855634
Elice F, Fink L, Tricot G, Barlogie B, Zangari M.
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Br J Haematol, 2006 Aug;134(4);399-405. PMID: 16882132
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
J Clin Oncol, 2006 Jul 1;24(19);3113-20. PMID: 16754936
Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA.
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Blood, 2006 Jul 1;108(1);403; author reply 404. PMID: 16790586
Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J.
Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations.
Leukemia, 2006 Jul;20(7);1288-90. PMID: 16688228
Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G.
Clinical and biological features of multiple myeloma involving the gastrointestinal system.
Haematologica, 2006 Jul;91(7);964-7. PMID: 16818286
Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC, .
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica, 2006 Jul;91(7);929-34. PMID: 16818280
Shaughnessy JD Jr.
Clinical use of genomics in multiple myeloma.
Clin Adv Hematol Oncol, 2006 Jun;4(6);419-21. PMID: 16981662
Stewart JP, Shaughnessy JD Jr.
Role of osteoblast suppression in multiple myeloma.
J Cell Biochem, 2006 May 1;98(1);1-13. PMID: 16440324
Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G.
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.
Clin Lymphoma Myeloma, 2006 May;6(6);469-74. PMID: 16796777
Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ.
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
Bone Marrow Transplant, 2006 May;37(9);857-64. PMID: 16532017
Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J.
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Blood, 2006 Apr 1;107(7);2633-8. PMID: 16322468
Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J Jr, Yaccoby S.
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Br J Haematol, 2006 Apr;133(1);83-92. PMID: 16512833
Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C, Depinho RA.
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Cancer Cell, 2006 Apr;9(4);313-25. PMID: 16616336
Epstein J, Walker R.
Myeloma and bone disease: "the dangerous tango".
Clin Adv Hematol Oncol, 2006 Apr;4(4);300-6. PMID: 16728940
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Cancer, 2006 Mar 15;106(6);1316-9. PMID: 16470606
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J.
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
N Engl J Med, 2006 Mar 9;354(10);1021-30. PMID: 16525139
Lee CK, Zangari M, Fassas A, Thertulien R, Talamo G, Badros A, Cottler-Fox M, van Rhee F, Barlogie B, Tricot G.
Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.
Bone Marrow Transplant, 2006 Mar;37(5);511-5. PMID: 16435020
Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
J Clin Oncol, 2006 Feb 20;24(6);929-36. PMID: 16432076
Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, Bauer K, Shaughnessy J, Tricot G.
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Mol Cancer Ther, 2006 Feb;5(2);457-66. PMID: 16505121
Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J.
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Haematologica, 2006 Feb;91(2);192-9. PMID: 16461303
Grazziutti ML, Dong L, Miceli MH, Cottler-Fox M, Krishna SG, Fassas A, van Rhee F, Barlogie BM, Anaissie EJ.
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients.
Bone Marrow Transplant, 2006 Feb;37(4);403-9. PMID: 16400338
Shaughnessy JD Jr, Barlogie B.
Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
Biol Blood Marrow Transplant, 2006 Jan;12(1 Suppl 1);77-80. PMID: 16399589
Bhattacharyya S, Epstein J, Suva LJ.
Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools.
Dis Markers, 2006;22(4);245-55. PMID: 17124346
Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J Jr, Kuehl WM.
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.
Cell Div, 2006;123. PMID: 17049078
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC, .
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood, 2005 Dec 1;106(12);3777-84. PMID: 16099887
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB.
Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.
J Am Dent Assoc, 2005 Dec;136(12);1658-68. PMID: 16383047
Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer, 2005 Nov 15;104(10);2141-8. PMID: 16206291
Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, Grazziutti ML, Purnell G, Fassas A, Tricot G, Barlogie B, Anaissie E.
18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes.
J Clin Oncol, 2005 Nov 1;23(31);7857-63. PMID: 16204017
Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F.
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Cancer Res, 2005 Nov 1;65(21);10041-9. PMID: 16267030
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC, .
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood, 2005 Nov 1;106(9);2977-81. PMID: 16020506
Yaccoby S.
The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
Clin Cancer Res, 2005 Nov 1;11(21);7599-606. PMID: 16278377
Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, Huang Y, Ogura T, Takahashi S, Ueda R, Barlogie B, Shaughnessy J Jr, Esumi H.
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
Oncogene, 2005 Oct 20;24(46);6936-44. PMID: 16044163
Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G.
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Br J Haematol, 2005 Oct;131(1);71-3. PMID: 16173965
Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J Jr, Rudikoff S.
Wnts induce migration and invasion of myeloma plasma cells.
Blood, 2005 Sep 1;106(5);1786-93. PMID: 15886323
Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E.
Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
J Clin Oncol, 2005 Aug 1;23(22);5217-23. PMID: 15955903
Fassas AB, Miceli MH, Grazzlutti M, Dong L, Barlogie B, Anaissie E.
Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation.
Leuk Lymphoma, 2005 Aug;46(8);1159-61. PMID: 16085556
Barlogie B.
The role of transplant in multiple myeloma.
Clin Adv Hematol Oncol, 2005 Aug;3(8);604-6. PMID: 16167043
Kamble R, Wilson CS, Fassas A, Desikan R, Siegel DS, Tricot G, Anderson P, Sawyer J, Anaissie E, Barlogie B.
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome.
Leuk Lymphoma, 2005 Aug;46(8);1137-42. PMID: 16085553
Hong H, Dragan Y, Epstein J, Teitel C, Chen B, Xie Q, Fang H, Shi L, Perkins R, Tong W.
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).
BMC Bioinformatics, 2005 Jul 15;6 Suppl 2S5. PMID: 16026602
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr.
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Blood, 2005 Jul 1;106(1);296-303. PMID: 15755896
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Harousseau JL, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J.
International staging system for multiple myeloma.
J Clin Oncol, 2005 May 20;23(15);3412-20. PMID: 15809451
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G.
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Blood, 2005 May 15;105(10);3939-44. PMID: 15671442
Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC, .
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer, 2005 Mar 15;103(6);1195-200. PMID: 15690325
Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD.
Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
Blood, 2005 Feb 1;105(3);1303-9. PMID: 15471949
Fassas A, Shaughnessy J, Barlogie B.
Cure of myeloma: hype or reality?
Bone Marrow Transplant, 2005 Feb;35(3);215-24. PMID: 15543196
Fassas A, Barlogie B, Feusner J, Kay NE, Wingard JR.
Highlights from the 46 th annual meeting of the American Society of Hematology.
Clin Adv Hematol Oncol, 2005 Feb;3(2);111-6. PMID: 16166978
Sawyer JR, Tricot G, Lukacs JL, Binz RL, Tian E, Barlogie B, Shaughnessy J Jr.
Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.
Genes Chromosomes Cancer, 2005 Jan;42(1);95-106. PMID: 15472896
Shaughnessy J.
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Hematology, 2005;10 Suppl 1117-26. PMID: 16188652
Epstein J, Yaccoby S.
The SCID-hu myeloma model.
Methods Mol Med, 2005;113183-90. PMID: 15968103
Szmania S, Yi Q, Cottler-Fox M, Rosen NA, Freeman J, Kordsmeier BJ, Moreno A, Shi J, Barlogie B, Tricot G, van Rhee F.
Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation.
Cytotherapy, 2005;7(4);374-84. PMID: 16162460
Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK.
Gene expression profiling and multiple myeloma.
Best Pract Res Clin Haematol, 2005;18(4);537-52. PMID: 16026736
Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G.
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Clin Cancer Res, 2004 Dec 15;10(24);8301-8. PMID: 15623606
Yata K, Yaccoby S.
The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Leukemia, 2004 Nov;18(11);1891-7. PMID: 15385929
Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD.
Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray.
Mod Pathol, 2004 Oct;17(10);1217-22. PMID: 15195108
Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Br J Haematol, 2004 Oct;127(2);165-72. PMID: 15461622
Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G.
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Br J Haematol, 2004 Sep;126(5);715-21. PMID: 15327525
Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J Jr, Reiman T.
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.
Blood, 2004 Aug 15;104(4);1151-8. PMID: 15105292
Herrera GA, Joseph L, Gu X, Hough A, Barlogie B.
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.
Arch Pathol Lab Med, 2004 Aug;128(8);875-9. PMID: 15270616
Miceli MH, Jones Jackson LB, Walker RC, Talamo G, Barlogie B, Anaissie EJ.
Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography.
Nucl Med Commun, 2004 Aug;25(8);813-8. PMID: 15266176
Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy J Jr.
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.
Br J Haematol, 2004 Jul;126(1);72-6. PMID: 15198734
Durie BG, Jacobson J, Barlogie B, Crowley J.
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
J Clin Oncol, 2004 May 15;22(10);1857-63. PMID: 15111617
Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N, Shaughnessy J Jr, Klein B.
The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.
Br J Haematol, 2004 May;125(3);373-82. PMID: 15086420
Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG, Razek H, Thorn B, Bissett JK, Anaissie EJ, Anaisse E, Barlogie B, Mehta JL.
Bradycardia during therapy for multiple myeloma with thalidomide.
Am J Cardiol, 2004 Apr 15;93(8);1052-5. PMID: 15081457
Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G.
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
Bone Marrow Transplant, 2004 Apr;33(8);823-8. PMID: 14767499
Tricot G, Barlogie B, Van Rhee F.
Treatment advances in multiple myeloma.
Br J Haematol, 2004 Apr;125(1);24-30. PMID: 15015964
Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J.
Cancer and the microenvironment: myeloma-osteoclast interactions as a model.
Cancer Res, 2004 Mar 15;64(6);2016-23. PMID: 15026338
Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A, Barlogie B.
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management.
Blood, 2004 Mar 1;103(5);1611-7. PMID: 14525792
Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H.
Genetics and cytogenetics of multiple myeloma: a workshop report.
Cancer Res, 2004 Feb 15;64(4);1546-58. PMID: 14989251
Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ.
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clin Cancer Res, 2004 Jan 1;10(1 Pt 1);88-95. PMID: 14734456
Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J.
Treatment of multiple myeloma.
Blood, 2004 Jan 1;103(1);20-32. PMID: 12969978
Hardin J, Waddell M, Page CD, Zhan F, Barlogie B, Shaughnessy J, Crowley JJ.
Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma.
Stat Appl Genet Mol Biol, 2004;3Article10. PMID: 16646788
Harousseau JL, Shaughnessy J Jr, Richardson P.
Multiple myeloma.
Hematology Am Soc Hematol Educ Program, 2004;237-56. PMID: 15561686
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr.
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
N Engl J Med, 2003 Dec 25;349(26);2483-94. PMID: 14695408
Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD.
High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Cancer Res, 2003 Dec 15;63(24);8749-56. PMID: 14695190
Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL.
Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
Blood, 2003 Nov 1;102(9);3100-7. PMID: 12855576
Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G.
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
Br J Haematol, 2003 Nov;123(3);484-9. PMID: 14617011
Barlogie B.
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Semin Hematol, 2003 Oct;40(4 Suppl 4);33-8. PMID: 15015894
Zhan F, Barlogie B, Shaughnessy J Jr.
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.
Semin Hematol, 2003 Oct;40(4);308-20. PMID: 14582081
Batchu RB, Moreno AM, Szmania S, Gupta SK, Zhan F, Rosen N, Kozlowski M, Spencer T, Spagnoli GC, Shaughnessy J, Barlogie B, Tricot G, van Rhee F.
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector.
Hum Gene Ther, 2003 Sep 20;14(14);1333-45. PMID: 14503968
Sherman AC, Coleman EA, Griffith K, Simonton S, Hine RJ, Cromer J, Latif U, Farley H, Garcia R, Anaissie EJ.
Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation.
Support Care Cancer, 2003 Sep;11(9);568-74. PMID: 12827482
Shaughnessy J Jr.
Primer on medical genomics. Part IX: scientific and clinical applications of DNA microarrays--multiple myeloma as a disease model.
Mayo Clin Proc, 2003 Sep;78(9);1098-109. PMID: 12962165
Zent CS, Zhan F, Schichman SA, Bumm KH, Lin P, Chen JB, Shaughnessy JD.
The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype.
Leuk Res, 2003 Sep;27(9);765-74. PMID: 12804633
Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ, .
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
Br J Haematol, 2003 Aug;122(3);441-50. PMID: 12877671
Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J.
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Br J Haematol, 2003 Aug;122(3);430-40. PMID: 12877670
Shaughnessy JD Jr, Barlogie B.
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.
Immunol Rev, 2003 Aug;194140-63. PMID: 12846813
Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD Jr, Stewart AK.
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
Blood, 2003 Jul 15;102(2);772-3. PMID: 12835230
Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G.
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
J Clin Oncol, 2003 Jul 15;21(14);2732-9. PMID: 12860952
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med, 2003 Jun 26;348(26);2609-17. PMID: 12826635
Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA.
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.
Blood, 2003 Jun 15;101(12);4982-9. PMID: 12609839
Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G.
The blood coagulation mechanism in multiple myeloma.
Semin Thromb Hemost, 2003 Jun;29(3);275-82. PMID: 12888931
Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G.
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Clin Lymphoma, 2003 Jun;4(1);32-5. PMID: 12837152
Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B.
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Blood, 2003 May 15;101(10);3849-56. PMID: 12531801
Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q.
Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.
Blood, 2003 May 15;101(10);4005-12. PMID: 12531797
Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J Jr, Bos NA.
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.
Br J Haematol, 2003 Apr;121(1);36-43. PMID: 12670329
Shaughnessy JD Jr.
Global gene expression profiling in the study of multiple myeloma.
Int J Hematol, 2003 Apr;77(3);213-25. PMID: 12731663
Munshi NC, Barlogie B.
Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia.
Semin Oncol, 2003 Apr;30(2);282-5. PMID: 12720153
Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr.
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Blood, 2003 Mar 15;101(6);2374-6. PMID: 12433679
Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E.
Infection--an underappreciated cause of bone pain in multiple myeloma.
Br J Haematol, 2003 Mar;120(6);1047-50. PMID: 12648075
Moehler TM, Ho AD, Goldschmidt H, Barlogie B.
Angiogenesis in hematologic malignancies.
Crit Rev Oncol Hematol, 2003 Mar;45(3);227-44. PMID: 12633837
Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr.
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
Blood, 2003 Feb 1;101(3);1128-40. PMID: 12393520
Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G.
Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
Br J Haematol, 2003 Feb;120(3);413-23. PMID: 12580955
Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G.
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Exp Hematol, 2003 Jan;31(1);73-80. PMID: 12543109
Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B.
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
Br J Haematol, 2003 Jan;120(1);44-52. PMID: 12492575
Epstein J, Yaccoby S.
Consequences of interactions between the bone marrow stroma and myeloma.
Hematol J, 2003;4(5);310-4. PMID: 14502254
Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.
Advances in biology and therapy of multiple myeloma.
Hematology Am Soc Hematol Educ Program, 2003;248-78. PMID: 14633785
Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J.
Antimyeloma efficacy of thalidomide in the SCID-hu model.
Blood, 2002 Dec 1;100(12);4162-8. PMID: 12393672
Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Bone Marrow Transplant, 2002 Dec;30(12);873-8. PMID: 12476279
Barlogie B, Shaughnessy J, Zangari M, Tricot G.
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Semin Oncol, 2002 Dec;29(6 Suppl 17);26-33. PMID: 12520482
Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G.
Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.
Br J Haematol, 2002 Oct;119(1);164-8. PMID: 12358921
Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B.
Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Leukemia, 2002 Sep;16(9);1835-7. PMID: 12200700
Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G.
Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.
Br J Haematol, 2002 Sep;118(4);1041-7. PMID: 12199783
Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Rème T, Legouffe E, Rossi JF, Shaughnessy J Jr, Ørntoft TF, Klein B.
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.
Blood, 2002 Aug 15;100(4);1113-22. PMID: 12149187
Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G.
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Blood, 2002 Aug 15;100(4);1168-71. PMID: 12149193
Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH.
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
Blood, 2002 Aug 1;100(3);961-5. PMID: 12130509
Min R, Li Z, Epstein J, Barlogie B, Yi Q.
Beta(2)-microglobulin as a negative growth regulator of myeloma cells.
Br J Haematol, 2002 Aug;118(2);495-505. PMID: 12139738
Shaughnessy JD Jr, Barlogie B.
Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myeloma.
Int J Hematol, 2002 Aug;76 Suppl 259-64. PMID: 12430902
Barlogie B Jr, Shaughnessy JD.
Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.
Int J Hematol, 2002 Aug;76 Suppl 1337-9. PMID: 12430877
Gubbins PO, Penzak SR, Polston S, McConnell SA, Anaissie E.
Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.
Pharmacotherapy, 2002 Aug;22(8);961-71. PMID: 12173799
Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD.
Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Blood, 2002 Jul 15;100(2);610-7. PMID: 12091355
Badros A, Morris C, Zangari M, Barlogie B, Tricot G.
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Leuk Lymphoma, 2002 Jun;43(6);1267-71. PMID: 12152995
Wen YJ, Min R, Tricot G, Barlogie B, Yi Q.
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Blood, 2002 May 1;99(9);3280-5. PMID: 11964294
Yi Q, Desikan R, Barlogie B, Munshi N.
Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Br J Haematol, 2002 May;117(2);297-305. PMID: 11972511
Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G.
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
Am J Med, 2002 Apr 1;112(5);412-3. PMID: 11904117
Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G.
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Blood Coagul Fibrinolysis, 2002 Apr;13(3);187-92. PMID: 11943931
Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G.
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
Br J Haematol, 2002 Apr;117(1);103-8. PMID: 11918539
Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G.
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
J Clin Oncol, 2002 Mar 1;20(5);1295-303. PMID: 11870172
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Blood, 2002 Mar 1;99(5);1745-57. PMID: 11861292
Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J.
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Br J Haematol, 2002 Feb;116(2);278-90. PMID: 11841428
Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M.
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
Transfusion, 2002 Feb;42(2);205-9. PMID: 11896336
Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B, .
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
Invest New Drugs, 2002 Feb;20(1);117-21. PMID: 12003187
Khassawneh BY, White P Jr, Anaissie EJ, Barlogie B, Hiller FC.
Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation.
Chest, 2002 Jan;121(1);185-8. PMID: 11796449
Ornstein DL, Ririe DW, Shaughnessy PJ, Neuhauser T, Bee C.
Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation.
Bone Marrow Transplant, 2002 Jan;29(1);71-4. PMID: 11840148
Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B.
Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.
Br J Haematol, 2002 Jan;116(1);211-7. PMID: 11841419
Barlogie B, Tricot G, Anaissie E.
Thalidomide in the management of multiple myeloma.
Semin Oncol, 2001 Dec;28(6);577-82. PMID: 11740812
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y.
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.
Proc Natl Acad Sci U S A, 2001 Sep 25;98(20);11581-6. PMID: 11562486
Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G.
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Blood, 2001 Sep 1;98(5);1614-5. PMID: 11520815
Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G.
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Br J Haematol, 2001 Sep;114(4);822-9. PMID: 11564069
Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G.
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.
Br J Haematol, 2001 Sep;114(3);600-7. PMID: 11552985
Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Blood, 2001 Jul 15;98(2);492-4. PMID: 11435324
Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, Kuehl M.
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Blood, 2001 Jul 1;98(1);217-23. PMID: 11418483
Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G.
Thalidomide in the management of multiple myeloma.
Semin Hematol, 2001 Jul;38(3);250-9. PMID: 11486313
Shaughnessy JD, Barlogie B.
Developmental therapeutics for multiple myeloma--a road map for the future.
Semin Hematol, 2001 Jul;38(3);295-7. PMID: 11486318
Barlogie B.
Introduction to therapies in multiple myeloma.
Semin Hematol, 2001 Jul;38(3);201-2. PMID: 11486306
Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G, Aniassie E.
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
Blood, 2001 May 1;97(9);2574-9. PMID: 11313244
Barlogie B.
High-dose therapy and innovative approaches to treatment of multiple myeloma.
Semin Hematol, 2001 Apr;38(2 Suppl 3);21-7. PMID: 11309705
Avva R, Vanhemert RL, Barlogie B, Munshi N, Angtuaco EJ.
CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities.
AJNR Am J Neuroradiol, 2001 Apr;22(4);781-5. PMID: 11290500
Wen YJ, Barlogie B, Yi Q.
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Blood, 2001 Mar 15;97(6);1750-5. PMID: 11238117
Lim SH, Badros A, Lue C, Barlogie B.
Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma.
Cancer, 2001 Mar 1;91(5);900-8. PMID: 11251941
Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK.
Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.
Br J Haematol, 2001 Mar;112(3);776-82. PMID: 11260083
Chiriva-Internati M, Du J, Cannon M, Barlogie B, Yi Q.
Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.
Br J Haematol, 2001 Feb;112(2);410-20. PMID: 11167840
Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B.
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.
Br J Haematol, 2001 Jan;112(1);242-7. PMID: 11167811
Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, Gilliland JC, Munshi NC, Tricot G, Shaughnessy JD Jr, Barlogie B.
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma.
Br J Haematol, 2001 Jan;112(1);167-74. PMID: 11167798
Børset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD.
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.
Blood, 2000 Oct 1;96(7);2528-36. PMID: 11001907
Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B.
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
Blood, 2000 Aug 15;96(4);1505-11. PMID: 10942398
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Blood, 2000 Jun 15;95(12);4008-10. PMID: 10845942
Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, Waage A, Sundan A, Börset M.
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Br J Haematol, 2000 Jun;109(4);815-22. PMID: 10929035
Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N.
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
Bone Marrow Transplant, 2000 Mar;25(5);483-7. PMID: 10713623
Gazitt Y, Shaughnessy P, Montgomery W.
Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2.
Cytokine, 1999 Dec;11(12);1010-9. PMID: 10623426
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B.
Antitumor activity of thalidomide in refractory multiple myeloma.
N Engl J Med, 1999 Nov 18;341(21);1565-71. PMID: 10564685
Yaccoby S, Epstein J.
The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.
Blood, 1999 Nov 15;94(10);3576-82. PMID: 10552969
Munshi NC, Barlogie B, Desikan KR, Wilson C.
Novel approaches in myeloma therapy.
Semin Oncol, 1999 Oct;26(5 Suppl 13);28-34. PMID: 10528892
Aslan T, Fassas AB, Desikan R, Siegel D, Munshi N, Mehta J, Singhal S, Barlogie B, Anaissie E.
Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy.
Bone Marrow Transplant, 1999 Sep;24(5);505-9. PMID: 10482934
Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J, Salmon SE, Barlogie B.
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
J Clin Oncol, 1999 Jul;17(7);2173-9. PMID: 10561273
Desikan KR, Dhodapkar MV, Munshi NC, Barlogie B.
Recent advances in the treatment of multiple myeloma.
Curr Opin Hematol, 1999 Jul;6(4);216-21. PMID: 10400369
Singhal S, Mehta J, Desikan K, Siegel D, Singh J, Munshi N, Spoon D, Anaissie E, Ayers D, Barlogie B.
Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy.
Bone Marrow Transplant, 1999 Jul;24(1);13-7. PMID: 10435728
Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G.
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
Br J Haematol, 1999 Jun;105(4);938-41. PMID: 10554803
Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS.
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.
Blood, 1999 May 1;93(9);3044-52. PMID: 10216101
Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G, Barlogie B.
Age is not a prognostic variable with autotransplants for multiple myeloma.
Blood, 1999 Jan 1;93(1);51-4. PMID: 9864145
Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Blood, 1999 Jan 1;93(1);55-65. PMID: 9864146
Fassas A, Jagannath S, Desikan KR, Shah HR, Shaver R, Waldron J, Munshi NC, Barlogie B, Tricot G.
Lymphomatoid granulomatosis following autologous stem cell transplantation.
Bone Marrow Transplant, 1999 Jan;23(1);79-81. PMID: 10037054
Shaughnessy J, Barlogie B.
Chromosome 13 deletion in myeloma.
Curr Top Microbiol Immunol, 1999;246199-203. PMID: 10396057
Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J, Barlogie B.
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
Blood, 1998 Dec 1;92(11);4269-78. PMID: 9834233
Thomas X, Anglaret B, Magaud JP, Epstein J, Archimbaud E.
Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.
Leuk Lymphoma, 1998 Dec;32(1-2);107-19. PMID: 10037006
Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B.
Biologic and therapeutic determinants of bone mineral density in multiple myeloma.
Leuk Lymphoma, 1998 Dec;32(1-2);121-7. PMID: 10037007
Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B.
Anti-myeloma activity of pamidronate in vivo.
Br J Haematol, 1998 Nov;103(2);530-2. PMID: 9827929
Yaccoby S, Barlogie B, Epstein J.
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
Blood, 1998 Oct 15;92(8);2908-13. PMID: 9763577
Grigorieva I, Thomas X, Epstein J.
The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Exp Hematol, 1998 Jul;26(7);597-603. PMID: 9657134
Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B.
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
Blood, 1998 Jun 15;91(12);4489-95. PMID: 9616143
Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R.
Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Bone Marrow Transplant, 1998 Jun;21(11);1101-7. PMID: 9645572
Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N, Bracy D, Barlogie B, Butch AW.
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.
Blood, 1998 May 1;91(9);3518-23. PMID: 9558413
Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Vesole D, Crowley J, Barlogie B.
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
Bone Marrow Transplant, 1998 May;21(9);887-92. PMID: 9613780
Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD.
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Blood, 1998 Apr 15;91(8);2679-88. PMID: 9531576
Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G.
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
J Clin Oncol, 1998 Apr;16(4);1547-53. PMID: 9552064
Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B.
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.
Blood, 1998 Mar 1;91(5);1732-41. PMID: 9473240
Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B, Tricot G.
Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
Leuk Lymphoma, 1998 Feb;28(5-6);501-8. PMID: 9613979
Barlogie B, Jagannath S, Tricot G, Desikan KR, Fassas A, Siegel D.
Advances in the treatment of multiple myeloma.
Adv Intern Med, 1998;43279-320. PMID: 9506186
Barlogie B.
Advances in therapy of multiple myeloma: lessons from acute leukemia.
Clin Cancer Res, 1997 Dec;3(12 Pt 2);2605-13. PMID: 10068262
Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD.
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
Br J Haematol, 1997 Nov;99(2);368-71. PMID: 9375756
Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, Barlogie B, Tricot G.
Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
Leuk Lymphoma, 1997 Oct;27(3-4);315-9. PMID: 9402328
Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B.
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma.
Bone Marrow Transplant, 1997 Sep;20(6);445-50. PMID: 9313876
Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G.
Peripheral stem cell mobilization and engraftment in patients over age 60.
Bone Marrow Transplant, 1997 Jul;20(1);1-3. PMID: 9232248
Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S, Munshi N, Vesole D, Mattox S, Bracy D, Barlogie B.
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.
Bone Marrow Transplant, 1997 Jul;20(2);113-6. PMID: 9244413
Singhal S, Mehta J, Barlogie B.
Advances in the treatment of multiple myeloma.
Curr Opin Hematol, 1997 Jul;4(4);291-7. PMID: 9260058
Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B.
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
J Clin Oncol, 1997 Jul;15(7);2659-66. PMID: 9215838
Jagannath S, Tricot G, Barlogie B.
Autotransplants in multiple myeloma: pushing the envelope.
Hematol Oncol Clin North Am, 1997 Apr;11(2);363-81. PMID: 9137975
Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R, Kornbluth J, Marcus S, Chiang Y, Ennist D, Kwak L, Reynolds C, Tricot G, Barlogie B.
Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir.
Blood, 1997 Feb 15;89(4);1334-40. PMID: 9028956
Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G.
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
Blood, 1997 Feb 1;89(3);789-93. PMID: 9028309
Epstein J.
Myeloma stem cell phenotype. Implications for treatment.
Hematol Oncol Clin North Am, 1997 Feb;11(1);43-9. PMID: 9081203
Barlogie B, Jagannath S, Epstein J, Munshi N, Siegel D, Desikan KR, Feinman R, Hsu PL, von Bremen K, Tricot G.
Biology and therapy of multiple myeloma in 1996.
Semin Hematol, 1997 Jan;34(1 Suppl 1);67-72. PMID: 9122748
Siegel DS, Terry JA, Koury J, Barlogie B, Epstein J, Feinman R.
Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells.
Curr Top Microbiol Immunol, 1997;224257-60. PMID: 9308249
Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, Tricot G.
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.
Br J Haematol, 1996 Nov;95(2);349-53. PMID: 8904891
Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B.
Autotransplants in multiple myeloma: what have we learned?
Blood, 1996 Aug 1;88(3);838-47. PMID: 8704239
Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B.
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Clin Cancer Res, 1996 Jun;2(6);947-52. PMID: 9816255
Grigoriev VG, Grigorieva I, Moerman EJ, Osborn CK, Epstein J, Crew MD.
Senescent fibroblasts as feeder cells for lymphoid cell cloning.
Anal Biochem, 1996 May 1;236(2);250-4. PMID: 8660501
Chen BJ, Epstein J.
Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells.
Blood, 1996 Mar 1;87(5);1972-6. PMID: 8634446
Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B.
Graft-versus-myeloma effect: proof of principle.
Blood, 1996 Feb 1;87(3);1196-8. PMID: 8562947
Gazitt Y, Tian E, Barlogie B, Reading CL, Vesole DH, Jagannath S, Schnell J, Hoffman R, Tricot G.
Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
Blood, 1996 Jan 15;87(2);805-11. PMID: 8555506
Vesole DH, Jagannath S, Tricot G, Desikan KR, Siegel D, Barlogie B.
Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma.
Cancer Invest, 1996;14(4);378-91. PMID: 8689434
Tricot GJ, Naucke S, Vaught L, Vesole D, Jagannath S, Barlogie B.
Is the risk of multiple myeloma increased in patients with silicone implants?
Curr Top Microbiol Immunol, 1996;210357-9. PMID: 8565577
Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR.
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
Blood, 1995 Dec 1;86(11);4250-6. PMID: 7492784
Epstein J, Hoover R, Kornbluth J, Barlogie B.
Biological aspects of multiple myeloma.
Baillieres Clin Haematol, 1995 Dec;8(4);721-34. PMID: 8845569
Chen BP, Fraser C, Reading C, Murray L, Uchida N, Galy A, Sasaki D, Tricot G, Jagannath S, Barlogie B.
Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.
Leukemia, 1995 Oct;9 Suppl 1S17-25. PMID: 7475307
Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B.
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.
Blood, 1995 Jul 15;86(2);685-91. PMID: 7605999
Sawyer JR, Waldron JA, Jagannath S, Barlogie B.
Cytogenetic findings in 200 patients with multiple myeloma.
Cancer Genet Cytogenet, 1995 Jul 1;82(1);41-9. PMID: 7627933
Gazitt Y, Reading CC, Hoffman R, Wickrema A, Vesole DH, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G.
Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
Blood, 1995 Jul 1;86(1);381-9. PMID: 7540887
Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B.
Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.
Bone Marrow Transplant, 1995 Jul;16(1);7-11. PMID: 7581132
Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B.
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Blood, 1995 Jan 15;85(2);588-96. PMID: 7529066
Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J.
Interleukin-6 prevents dexamethasone-induced myeloma cell death.
Blood, 1994 Nov 1;84(9);3063-70. PMID: 7949178
Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon SE, Barlogie B.
Hemopoietic stem cell transplants for multiple myeloma.
Oncology (Williston Park), 1994 Nov;8(11);89-103; discussion 103-6. PMID: 7826841
Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
J Clin Oncol, 1994 Nov;12(11);2405-14. PMID: 7964957
Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J.
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
Blood, 1994 Aug 1;84(3);950-6. PMID: 7913845
Barlogie B, Vesole DH, Jagannath S.
Salvage therapy for multiple myeloma: the University of Arkansas experience.
Mayo Clin Proc, 1994 Aug;69(8);787-95. PMID: 8035638
Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G.
Deletion of the retinoblastoma gene in multiple myeloma.
Leukemia, 1994 Aug;8(8);1280-4. PMID: 8057662
Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R.
Limited value of myeloablative therapy for late multiple myeloma.
Blood, 1994 Jan 15;83(2);512-6. PMID: 7904486
Barlogie B, Jagannath S, Vesole D, Tricot G.
Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.
J Hematother, 1994;3(2);149-53. PMID: 7922016
Barlogie B, Crowley J, Salmon SE, Bonnet J, Weick JK, Hayden K.
Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study.
Invest New Drugs, 1994;12(1);53-5. PMID: 7960607
Barlogie B.
Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.
Semin Hematol, 1993 Oct;30(4 Suppl 6);25-7. PMID: 8153675
Barlogie B.
Hemopoietic stem cell transplant for multiple myeloma (MM).
Leukemia, 1993 Jul;7(7);1095. PMID: 8100602
Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J.
Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells.
Blood, 1993 Jun 15;81(12);3357-64. PMID: 8507873
Vesole DH, Jagannath S, Glenn L, Barlogie B.
Autotransplantation in multiple myeloma.
Hematol Oncol Clin North Am, 1993 Jun;7(3);613-30. PMID: 8102136
Barlogie B, Beck T.
Recombinant human erythropoietin and the anemia of multiple myeloma.
Stem Cells, 1993 Mar;11(2);88-94. PMID: 8457789
Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD.
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.
Blood, 1993 Feb 1;81(3);767-74. PMID: 8427968
Barlogie B, Alexanian R, Jagannath S.
Plasma cell dyscrasias.
JAMA, 1992 Nov 25;268(20);2946-51. PMID: 1433713
Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B.
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
Blood, 1992 Oct 1;80(7);1666-72. PMID: 1391937
Barlogie B, Gale RP.
Multiple myeloma and chronic lymphocytic leukemia: parallels and contrasts.
Am J Med, 1992 Oct;93(4);443-50. PMID: 1415309
Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B.
Primary dexamethasone treatment of multiple myeloma.
Blood, 1992 Aug 15;80(4);887-90. PMID: 1498331
Barlogie B, Epstein J, Selvanayagam P, Alexanian R.
[Plasma-cell myeloma. II. New developments in the diagnosis and treatment of the disease]
Gematol Transfuziol, 1992 Jul-Aug;37(7-8);33-9. PMID: 1342986
Kreitman RJ, Siegall CB, FitzGerald DJ, Epstein J, Barlogie B, Pastan I.
Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.
Blood, 1992 Apr 1;79(7);1775-80. PMID: 1558971
Epstein J.
Myeloma phenotype: clues to disease origin and manifestation.
Hematol Oncol Clin North Am, 1992 Apr;6(2);249-56. PMID: 1582972
Jagannath S, Barlogie B.
Autologous bone marrow transplantation for multiple myeloma.
Hematol Oncol Clin North Am, 1992 Apr;6(2);437-49. PMID: 1582984
Barlogie B, Jagannath S.
Autotransplants in myeloma.
Bone Marrow Transplant, 1992;10 Suppl 137-44. PMID: 1355685
Thomas X, Xiao HQ, Chang R, Epstein J.
Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population.
Curr Top Microbiol Immunol, 1992;182201-7. PMID: 1490355
Barlogie B.
Pathophysiology of human multiple myeloma--recent advances and future directions.
Curr Top Microbiol Immunol, 1992;182245-50. PMID: 1490361
Dimopoulos MA, Barlogie B, Smith TL, Alexanian R.
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Ann Intern Med, 1991 Dec 15;115(12);931-5. PMID: 1952489
Barlogie B.
Toward a cure for multiple myeloma?
N Engl J Med, 1991 Oct 31;325(18);1304-6. PMID: 1922227
Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J.
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Semin Oncol, 1991 Oct;18(5 Suppl 7);33-6. PMID: 1948127
Barlogi B, Epstein J, Selvaniagam P, Alexanian R.
[Plasma cell myeloma. I. A new concept of disease biology]
Gematol Transfuziol, 1991 Aug;36(8);29-35. PMID: 1752407
Alexanian R, Barlogie B, Gutterman J.
Alpha-interferon combination therapy of resistant myeloma.
Am J Clin Oncol, 1991 Jun;14(3);188-92. PMID: 2031504
Barlogie B, Gahrton G.
Bone marrow transplantation in multiple myeloma.
Bone Marrow Transplant, 1991 Feb;7(2);71-9. PMID: 2049563
Barlogie B, Alexanian R.
Second International Workshop on Myeloma: advances in biology and therapy of multiple myeloma.
Cancer Res, 1989 Dec 15;49(24 Pt 1);7172-5. PMID: 2479477
Barlogie B, Velasquez WS, Alexanian R, Cabanillas F.
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
J Clin Oncol, 1989 Oct;7(10);1514-7. PMID: 2778481
Epstein J, Xiao HQ, Oba BK.
P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.
Blood, 1989 Aug 15;74(3);913-7. PMID: 2568864
Barlogie B, Smallwood L, Smith T, Alexanian R.
High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.
Ann Intern Med, 1989 Apr 1;110(7);521-5. PMID: 2647015
Barlogie B, Epstein J, Selvanayagam P, Alexanian R.
Plasma cell myeloma--new biological insights and advances in therapy.
Blood, 1989 Mar;73(4);865-79. PMID: 2465790
Alexanian R, Barlogie B, Ventura G.
Chemotherapy for resistant and relapsing multiple myeloma.
Eur J Haematol Suppl, 1989;51140-4. PMID: 2576405
Barlogie B, Alexanian R.
Prognostic factors in multiple myeloma: the M.D. Anderson experience.
Eur J Haematol Suppl, 1989;5184-7. PMID: 2627993
Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F.
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Blood, 1988 Dec;72(6);2015-9. PMID: 3196876
Lee TM, Grammer LC, Shaughnessy MA.
Estimation of IgE antibody with a nonisotopic technique with no interference of isotypic antibodies.
J Allergy Clin Immunol, 1988 Nov;82(5 Pt 1);812-7. PMID: 3192864
